Abstract
BackgroundCervical cancer is the most common gynecological malignancy with low terminal cure rate, and therefore new therapeutic targets are urgently needed to combat this disease. SMYD2, as an oncogene, is abnormal highly expressed in multiple types of tumors and further affects the occurrence and development, but the potential correlations between SMYD2 expression and cervical cancer progression is still unclear.MethodsWe first used the bioinformatics website to screen the data of cervical cancer in (The Cancer Genome Atlas) TCGA and survival analysis was used to find the different survival rates in the SMYD2 high expression group and low expression group. Through immunohistochemistry, the association between SMYD2 expression and clinical-pathological features of cervical cancer patients was further evaluated. Quantitative PCR and Immunoblot were applied to investigate the relative mRNA and protein expression levels, respectively. In vivo and in vitro experiments were performed to explore the function of SMYD2 in cancer progression.ResultsWe first found a high expression of SMYD2 in cervical cancer, and survival analysis found that the poorer survival rate in the SMYD2 high expression group than that in the low expression group. Herein, our study demonstrated that the expression of SMYD2 in patients with cervical cancer was associated with FIGO stage, tumor size and further correlated with poor prognosis. Our data further showed that the inhibition of SMYD2 expression in cervical cancer cell line Caski and Siha could dramatically block the proliferation of cervical cancer cells. Additionally, SMYD2-shRNA lentivirus infected remarkably inhibited tumorigenesis in mice compared with the scramble group.ConclusionsTaken together, this study provides strong evidence of the involvement of SMYD2 in cervical cancer growth and indicates that it could have high potential as a therapeutic target of cervical cancer.
Highlights
Cervical cancer is the most common gynecological malignancy with low terminal cure rate, and new therapeutic targets are urgently needed to combat this disease
Bioinformatic analysis of SET and MYND domain-containing protein 2 (SMYD2) in cervical cancer patients Bioinformatic method were performed to analyze the expression of SMYD2 at mRNA levels in cervical cancer patients by using GEPIA, an online analytical database that analyze cases from TCGA, and we found that SMYD2 was abnormal highly expressed in the cervical cancer tissues compared with normal tissues (Fig. 1a, P < 0.05, http://gepia.cancer-pku.cn/detail.php?gene=SMYD2)
A total of 306 cervical cancer cases of TCGA patients were analyzed, and the median SMYD2 mRNA expression was used as the cutoff point to divide all the patients into high and low expression groups according to the median
Summary
Cervical cancer is the most common gynecological malignancy with low terminal cure rate, and new therapeutic targets are urgently needed to combat this disease. Cervical cancer is the most common gynecological malignancy [1]. The treatment of cervical cancer mainly focuses on surgery and radiotherapy, but the survival rates of patients with advanced stage is very low, and the. 5-year survival rates of invasive cervical cancer is only 67% [5, 6]. Early cervical cancer has no obvious symptoms, which increases the difficulty of diagnosis [7]. In order to combat this disease, improved early diagnosis is requirement, novel and promising therapeutic targets are urgly needed [8]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
